Table of Contents Author Guidelines Submit a Manuscript

An erratum for this article has been published. To view the erratum, please click here.

Experimental Diabetes Research
Volume 2012, Article ID 896362, 7 pages
Research Article

Circulating Levels of MicroRNA from Children with Newly Diagnosed Type 1 Diabetes and Healthy Controls: Evidence That miR-25 Associates to Residual Beta-Cell Function and Glycaemic Control during Disease Progression

1Department of Pediatrics, Herlev Hospital, 2730 Herlev, Denmark
2Faculty of Health Sciences, University of Copenhagen, 2200 Copenhagen, Denmark
3Jiangsu Engineering Research Center for microRNA Biology and Biotechnology, State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing 210093, China
4Department of Growth and Reproduction, Rigshospitalet and Faculty of Health Sciences, University of Copenhagen, 2100 Copenhagen, Denmark
5Glostrup Research Institute, Glostrup Hospital and Center for Non-Coding RNA in Technology and Health, University of Copenhagen, 2600 Glostrup, Denmark
6Department of Statistics, University of Southern Denmark, 5000 Odense, Denmark

Received 13 February 2012; Revised 11 May 2012; Accepted 17 May 2012

Academic Editor: Anandwardhan Hardikar

Copyright © 2012 Lotte B. Nielsen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


This study aims to identify key miRNAs in circulation, which predict ongoing beta-cell destruction and regeneration in children with newly diagnosed Type 1 Diabetes (T1D). We compared expression level of sera miRNAs from new onset T1D children and age-matched healthy controls and related the miRNAs expression levels to beta-cell function and glycaemic control. Global miRNA sequencing analyses were performed on sera pools from two T1D cohorts (n = 275 and 129, resp.) and one control group (n = 151). We identified twelve upregulated human miRNAs in T1D patients (miR-152, miR-30a-5p, miR-181a, miR-24, miR-148a, miR-210, miR-27a, miR-29a, miR-26a, miR-27b, miR-25, miR-200a); several of these miRNAs were linked to apoptosis and beta-cell networks. Furthermore, we identified miR-25 as negatively associated with residual beta-cell function (est.: −0.12, P = 0.0037), and positively associated with glycaemic control (HbA1c) (est.: 0.11, P = 0.0035) 3 months after onset. In conclusion this study demonstrates that miR-25 might be a “tissue-specific” miRNA for glycaemic control 3 months after diagnosis in new onset T1D children and therefore supports the role of circulating miRNAs as predictive biomarkers for tissue physiopathology and potential intervention targets.